$0.19
arrow_drop_up0.74%Key Stats | |
---|---|
Open | $0.18 |
Prev. Close | $0.18 |
EPS | -1.49 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $12.37M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 0.18 | 0.19 |
52 Week Range | 0.16 | 6.79 |
Ratios | |
---|---|
EPS | -1.49 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
Where Lyra Therapeutics Stands With Analysts
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update